Johnson & Johnson Price to Free Cash Flow Ratio 2010-2025 | JNJ
Historical price to free cash flow ratio values for Johnson & Johnson (JNJ) since 2010.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Johnson & Johnson Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2025-06-03 |
154.42 |
|
17.76 |
| 2025-03-31 |
164.43 |
$8.70 |
18.91 |
| 2024-12-31 |
142.26 |
$8.45 |
16.84 |
| 2024-09-30 |
158.14 |
$8.69 |
18.19 |
| 2024-06-30 |
141.55 |
$8.48 |
16.69 |
| 2024-03-31 |
151.97 |
$7.59 |
20.02 |
| 2023-12-31 |
149.45 |
$7.27 |
20.57 |
| 2023-09-30 |
147.32 |
$6.28 |
23.46 |
| 2023-06-30 |
155.43 |
$5.63 |
27.63 |
| 2023-03-31 |
144.47 |
$6.23 |
23.18 |
| 2022-12-31 |
163.47 |
$6.65 |
24.56 |
| 2022-09-30 |
150.20 |
$6.80 |
22.10 |
| 2022-06-30 |
162.12 |
$7.60 |
21.32 |
| 2022-03-31 |
160.83 |
$7.52 |
21.40 |
| 2021-12-31 |
154.25 |
$7.65 |
20.15 |
| 2021-09-30 |
144.68 |
$8.72 |
16.58 |
| 2021-06-30 |
146.71 |
$8.77 |
16.73 |
| 2021-03-31 |
145.45 |
$8.14 |
17.87 |
| 2020-12-31 |
138.42 |
$7.67 |
18.04 |
| 2020-09-30 |
130.04 |
$6.91 |
18.82 |
| 2020-06-30 |
122.02 |
$6.65 |
18.35 |
| 2020-03-31 |
113.00 |
$8.50 |
13.29 |
| 2019-12-31 |
124.90 |
$8.64 |
14.46 |
| 2019-09-30 |
110.02 |
$9.35 |
11.77 |
| 2019-06-30 |
117.56 |
$8.74 |
13.45 |
| 2019-03-31 |
117.19 |
$8.04 |
14.57 |
| 2018-12-31 |
107.47 |
$7.97 |
13.49 |
| 2018-09-30 |
114.34 |
$7.48 |
15.29 |
| 2018-06-30 |
99.74 |
$7.70 |
12.95 |
| 2018-03-31 |
104.57 |
$7.36 |
14.20 |
| 2017-12-31 |
113.28 |
$7.14 |
15.86 |
| 2017-09-30 |
104.77 |
$7.11 |
14.73 |
| 2017-06-30 |
105.93 |
$6.62 |
16.00 |
| 2017-03-31 |
99.08 |
$6.33 |
15.65 |
| 2016-12-31 |
91.04 |
$6.03 |
15.11 |
| 2016-09-30 |
92.71 |
$5.86 |
15.81 |
| 2016-06-30 |
94.57 |
$6.19 |
15.27 |
| 2016-03-31 |
83.76 |
$6.66 |
12.58 |
| 2015-12-31 |
78.94 |
$6.96 |
11.35 |
| 2015-09-30 |
71.22 |
$6.13 |
11.62 |
| 2015-06-30 |
73.79 |
$6.80 |
10.85 |
| 2015-03-31 |
75.61 |
$6.56 |
11.53 |
| 2014-12-31 |
78.05 |
$6.85 |
11.39 |
| 2014-09-30 |
79.04 |
$6.76 |
11.70 |
| 2014-06-30 |
77.06 |
$5.83 |
13.23 |
| 2014-03-31 |
71.85 |
$5.49 |
13.08 |
| 2013-12-31 |
66.52 |
$4.96 |
13.40 |
| 2013-09-30 |
62.52 |
$4.94 |
12.67 |
| 2013-06-30 |
61.46 |
$4.71 |
13.04 |
| 2013-03-31 |
57.93 |
$4.64 |
12.48 |
| 2012-12-31 |
49.41 |
$4.97 |
9.95 |
| 2012-09-30 |
48.15 |
$5.02 |
9.59 |
| 2012-06-30 |
46.78 |
$5.05 |
9.26 |
| 2012-03-31 |
45.23 |
$4.83 |
9.37 |
| 2011-12-31 |
44.58 |
$4.59 |
9.71 |
| 2011-09-30 |
42.89 |
$4.62 |
9.28 |
| 2011-06-30 |
44.40 |
$4.71 |
9.43 |
| 2011-03-31 |
39.21 |
$4.72 |
8.31 |
| 2010-12-31 |
40.56 |
$5.21 |
7.79 |
| 2010-09-30 |
40.29 |
$5.76 |
6.99 |
| 2010-06-30 |
38.04 |
$5.69 |
6.69 |
| 2010-03-31 |
41.62 |
$5.50 |
7.56 |
| 2009-12-31 |
40.80 |
$5.15 |
7.93 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$371.546B |
$88.821B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
